The Lead Episode 39: A Discussion of The Feasibility and Safety of Flecainide Use Among Patients with Varying Degrees of Coronary Disease

Discussion Topic: The Feasibility and Safety of Flecainide Use Among Patients with Varying Degrees of Coronary Disease

Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College, discusses the CAST trial with David J. Callans, MD, FHRS, CCDS of Hospital of the University of Pennsylvania, and Gerald V Naccarelli, MD, FHRS of Pennsylvania State University Milton S. Hershey Medical Center. Class IC antiarrhythmic drugs have been generally avoided in patients with any degree of coronary disease and any type of cardiomyopathy, whether or not they fit the inclusion criteria of the trial. For the past 3+ decades, the CAST trial results have been extrapolated to a broader population despite a lack of evidence. In this study, the authors retrospectively look at the safety of these agents compared with Class III drugs in patients with atrial fibrillation and varying degrees of CAD.

Host: Jason T. Jacobson, MD, FHRS
Guests: David J. Callans, MD, FHRS, CCDS and Gerald V. Naccarelli, MD, FHRS

Speaker and Article Information: Download

• Listen on HRS365
• Listen on Apple Podcasts
• Listen on Spotify